Access to patient-level trial data--a boon to drug developers.


n engl j med 369;17 october 24, 2013 1577 making a case on the basis of respect for patients’ altruism, the need to safeguard public health, and distrust in the integrity and completeness of published trial information.1 We at the European Medicines Agency (EMA) have been actively engaged in this debate, and the EMA has recently published a draft… (More)
DOI: 10.1056/NEJMp1310771


Blog articles referencing this paper

  • Reading list

    The Incidental Economist · Oct 27, 2013

  • Don't see an article that should be here?